MiaPaCa-2 xenografts SHP2i + ERKi
Ontology highlight
ABSTRACT: KRAS mutant pancreatic tumors have poor prognosis and few therapeutic options. Here, Frank et al. show that the combination of RMC4550 (SHP2 inhibitor) and LY3214996 (ERK inhibitor) effectively impairs tumor growth and induces tumor regression in multiplein vivo models of PDAC .
ORGANISM(S): Homo sapiens
PROVIDER: GSE213697 | GEO | 2022/11/15
REPOSITORIES: GEO
ACCESS DATA